The Effect of Preoperative Maxigesic® on Intraoperative Remifentanil Requirement

Sponsor
Ajou University School of Medicine (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT06015711
Collaborator
(none)
96
1
2
16.1
6

Study Details

Study Description

Brief Summary

Maxigesic is combined intravenous analgesic of ibuprofen and acetaminphen. The purpose of this study is investigate weather preoperative Maxigesic administration can reduce intraoperative remifentanil requirement.

Condition or Disease Intervention/Treatment Phase
  • Drug: Maxigesic administration
N/A

Detailed Description

Remifentanil is an ultra-short-acting opioid that is useful during surgery because of its fast onset and recovery. However, because of this profile, it is known that the use of high doses of remifentanil during surgery paradoxically increases postoperative pain. It has been reported that intraoperative remifentanil use resulted in higher pain scores 2 hours after surgery compared to intraoperative dexmedetomidine, and that the incidence of hypotension, tremor, and postoperative nausea and vomiting were higher in the remifentanil group. Therefore, minimizing the use of remifentanil during surgery is clinically meaningful.

Nonsteroidal anti-inflammatory drugs (NSAIDs) play an important role in multimodal analgesia, and are known to reduce the use of opioids when used together with opioids in postoperative pain [3]. It has also been reported that preoperative administration of ibuprofen reduces postoperative opioid use. Administration of acetaminophen has also been reported to reduce opioid usage. However, there is no study on whether the administration of these NSAIDs and acetaminophen reduces the opioid requirement used during surgery, not after surgery.

The Analgesia nociception index (ANI, MDoloris medical system, France) was developed to measure real-time nociception in patients undergoing surgery under general anesthesia. This index measures parasympathetic nerve activity based on heart rate variability. It is known to be superior in detecting nociceptive stimuli rather than judging only by existing pulse rate and blood pressure. In addition, since information is provided as an objectified numerical value, analgesic drugs can be adjusted during surgery based on this information. This helps to provide an appropriate amount of opioids during surgery when needed, and can prevent overdose. A previous study reported that when ANI-guided remifentanil infusion was performed, the amount of remifentanil used was reduced compared to conventional control of remifentanil only with blood pressure and pulse rate.

Maxigesic® is a combination of acetaminophen and ibuprofen, and is a drug that rapidly relieves various types of pain. It is known to be more effective in relieving postoperative pain than single acetaminophen or ibuprofen. The hypothesis of this study is that administration of Maxigesic®, a combination of acetaminophen and NSAIDs, reduces intraoperative remifentanil requirement. This study aims to investigate whether preoperative Maxigesic® administration can reduce intraoperative remifentanil requirements by performing ANI-guided remifentanil infusion for objective control of remifentanil administration.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
96 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Triple (Participant, Care Provider, Outcomes Assessor)
Primary Purpose:
Other
Official Title:
The Effect of Preoperative Maxigesic® Administration on Analgesic Nociception Index (ANI) Guided Remifentanil Administration
Anticipated Study Start Date :
Aug 30, 2023
Anticipated Primary Completion Date :
Aug 31, 2024
Anticipated Study Completion Date :
Dec 31, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: Maxigesic group

Administration of Maxigesic before surgery start.

Drug: Maxigesic administration
Preoperative Maxigesic IV administration
Other Names:
  • Preoperative Maxigesic administration
  • No Intervention: Control group

    Administration of normal saline before surgery start.

    Outcome Measures

    Primary Outcome Measures

    1. Remifentanil requirement [3 hours, from incision to skin closure]

      Intraoperative remifentanil requirement

    Secondary Outcome Measures

    1. postoperative analgesic requirement [1 hour, while in the recovery room]

      postoperative fentanyl requirement

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    19 Years to 60 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Adult patients (19-60 years old) with ASA physical status 1, 2, 3

    • Scheduled surgery under general anesthesia

    Exclusion Criteria:
    • The patient does not conset

    • Pregnancy

    • hepatic disorder

    • Renal disorder

    • Asthma

    • Hypersensitivity to the NSAIDs or acetaminophen

    • Patients receiving chronic pain therapy

    • Drug dependence

    • Patients taking psychiatric drugs

    • Alcoholics

    • History of gastrointestinal ulcer or bleeding

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Ajou university school of medicine Suwon Gyeonggi-do Korea, Republic of 16499

    Sponsors and Collaborators

    • Ajou University School of Medicine

    Investigators

    • Principal Investigator: In Kyong Yi, MD, Ajou University School of Medicine

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    In-kyong Yi, Assitant professor, Ajou University School of Medicine
    ClinicalTrials.gov Identifier:
    NCT06015711
    Other Study ID Numbers:
    • AJOUIRB-IV-2023-400
    First Posted:
    Aug 29, 2023
    Last Update Posted:
    Aug 29, 2023
    Last Verified:
    Aug 1, 2023
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No

    Study Results

    No Results Posted as of Aug 29, 2023